Universal markers of thyroid malignancies: Galectin-3, HBME-1, and Cytokeratin-19

Difficulties in diagnosis of thyroid lesions, even with histologic analysis, are well known. This study has been carried on to evaluate the role of immunohistochemical markers including galectin-3, Hector Battifora mesothelial cell-1 (HBME-1), and cytokeratin-19 in the diagnosis and differential diagnosis of benign and malignant thyroid lesions. The expressions of galectin-3, HBME-1, and cytokeratin-19 were tested in formalin-fixed, paraffin-embedded tissues from 458 surgically resected thyroid lesions including non-neoplastic and neoplastic lesions. Immunostaining with standard avidin-biotin complex technique was performed by using monoclonal antibodies. In malignant neoplastic thyroid lesions, galectin-3, HBME-1, and cytokeratin-19 were diffusely expressed in general. Diffuse expression rates of these three markers were 72.3% (47/65), 70.7% (46/65), and 76.9% (50/65), respectively. The use of galectin-3, HBME-1, and cytokeratin-19 may provide significant contributions in the differential diagnosis of malignant thyroid tumors. Although focal galectin-3, HBME-1, and cytokeratin-19 expression may be encountered in benign lesions, diffuse positive reactions for these three markers are characteristic of malignant lesions. It has concluded that cytokeratin-19 alone and its combinations with other markers were more sensitive in accurate diagnosis of papillary carcinoma than the other combinations; meanwhile, there were similar results for follicular carcinomas with HBME-1 alone and its combinations. © 2009 Springer Science+Business Media, LLC.

Dergi Adı Endocrine Pathology
Dergi Cilt Bilgisi 21
Dergi Sayısı 2
Sayfalar 80 - 89
Yayın Yılı 2010
Eser Adı
[dc.title]
Universal markers of thyroid malignancies: Galectin-3, HBME-1, and Cytokeratin-19
Yazar
[dc.contributor.author]
Barut F.
Yazar
[dc.contributor.author]
Kandemir N.O.
Yazar
[dc.contributor.author]
Bektas S.
Yazar
[dc.contributor.author]
Bahadir B.
Yazar
[dc.contributor.author]
Keser S.
Yazar
[dc.contributor.author]
Ozdamar S.O.
Yayın Yılı
[dc.date.issued]
2010
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Difficulties in diagnosis of thyroid lesions, even with histologic analysis, are well known. This study has been carried on to evaluate the role of immunohistochemical markers including galectin-3, Hector Battifora mesothelial cell-1 (HBME-1), and cytokeratin-19 in the diagnosis and differential diagnosis of benign and malignant thyroid lesions. The expressions of galectin-3, HBME-1, and cytokeratin-19 were tested in formalin-fixed, paraffin-embedded tissues from 458 surgically resected thyroid lesions including non-neoplastic and neoplastic lesions. Immunostaining with standard avidin-biotin complex technique was performed by using monoclonal antibodies. In malignant neoplastic thyroid lesions, galectin-3, HBME-1, and cytokeratin-19 were diffusely expressed in general. Diffuse expression rates of these three markers were 72.3% (47/65), 70.7% (46/65), and 76.9% (50/65), respectively. The use of galectin-3, HBME-1, and cytokeratin-19 may provide significant contributions in the differential diagnosis of malignant thyroid tumors. Although focal galectin-3, HBME-1, and cytokeratin-19 expression may be encountered in benign lesions, diffuse positive reactions for these three markers are characteristic of malignant lesions. It has concluded that cytokeratin-19 alone and its combinations with other markers were more sensitive in accurate diagnosis of papillary carcinoma than the other combinations; meanwhile, there were similar results for follicular carcinomas with HBME-1 alone and its combinations. © 2009 Springer Science+Business Media, LLC.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Cytokeratin-19
Konu Başlıkları
[dc.subject]
Differential diagnosis
Konu Başlıkları
[dc.subject]
Galectin-3
Konu Başlıkları
[dc.subject]
HBME-1
Konu Başlıkları
[dc.subject]
Thyroid lesions
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
1046-3976
İlk Sayfa Sayısı
[dc.identifier.startpage]
80
Son Sayfa Sayısı
[dc.identifier.endpage]
89
Dergi Adı
[dc.relation.journal]
Endocrine Pathology
Dergi Sayısı
[dc.identifier.issue]
2
Dergi Cilt Bilgisi
[dc.identifier.volume]
21
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1007/s12022-010-9114-y
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/8442
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
183
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
25 Mayıs 2024 00:28
Google Kontrol
Tıklayınız
lesions cytokeratin-19 thyroid diagnosis HBME-1 galectin-3 markers malignant combinations differential including benign neoplastic expression diffuse positive encountered contributions Although tumors significant provide respectively (50/65) (46/65) reactions Difficulties characteristic similar Science+Business Springer carcinomas follicular results meanwhile
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms